Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.96 and traded as high as $1.58. Ironwood Pharmaceuticals shares last traded at $1.56, with a volume of 601,507 shares.

Analysts Set New Price Targets

Several analysts recently issued reports on IRWD shares. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.94.

Ironwood Pharmaceuticals Stock Performance

The firm has a 50 day simple moving average of $1.34 and a two-hundred day simple moving average of $0.96. The stock has a market cap of $253.40 million, a P/E ratio of -31.19 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The firm had revenue of $85.24 million for the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Institutional Trading of Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of IRWD. Cerity Partners LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth $142,000. CWM LLC raised its stake in shares of Ironwood Pharmaceuticals by 801.1% in the 1st quarter. CWM LLC now owns 57,001 shares of the biotechnology company’s stock worth $84,000 after buying an additional 50,675 shares in the last quarter. Allianz Asset Management GmbH raised its stake in shares of Ironwood Pharmaceuticals by 411.5% in the 1st quarter. Allianz Asset Management GmbH now owns 293,100 shares of the biotechnology company’s stock worth $431,000 after buying an additional 235,800 shares in the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of Ironwood Pharmaceuticals by 162.6% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company’s stock worth $58,000 after buying an additional 24,635 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its holdings in shares of Ironwood Pharmaceuticals by 719.8% in the 1st quarter. KLP Kapitalforvaltning AS now owns 198,400 shares of the biotechnology company’s stock worth $292,000 after acquiring an additional 174,200 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.